SIGA Technologies Third Quarter 2026 Earnings Call - SIGA TECHNOLOGIES INC

Financial Performance:

• Nine-month product revenue totaled approximately $42 million (mostly recognized in Q2), driven by $26 million in U.S. government IV TPOC deliveries and $13 million in international sales.
• Research and development revenue was approximately $7 million for the nine-month period, with $1 million earned in Q3.
• Pre-tax operating income for the nine months ended September 30, 2026, was approximately $2 million; however, Q3 saw a pre-tax operating loss of approximately $7 million.
• Net income for the nine-month period was approximately $6 million (9 cents per share), while Q3 reported a net loss of $3 million (4 cents per share).
• The company maintains a strong balance sheet with $116 million in cash and zero debt as of September 30, 2026.
• Revenue distribution remains variable, with significant product deliveries concentrated in Q2 and no product sales recorded in Q3.

Guidance and Future Outlook:

• Management expects the supplemental NDA filing for the Post-Exposure Prophylaxis (PEP) program to occur in 2028, delayed from previous expectations due to additional FDA validation requirements.
• Pediatric formulation Phase 1 results are expected by year-end to inform future development steps for extending TPOC coverage to infants.
• A new U.S. government contract award is anticipated despite an uncertain timeline; the procurement process is moving slower than historical precedents.
• Management projects continued revenue diversification through international contracts, with advanced negotiations ongoing for a late-stage international deal.

Business Segments and Product Lines:

• Secured a five-year contract with Canada's Department of National Defence (CDND) for oral TPOCs, valued up to $15 million ($9 million firm commitment over three years, $6 million options).
• Final product delivery under the BARDA 19C contract was completed in Q2, fulfilling all U.S. government obligations for that agreement.
• Product portfolio includes oral, IV, and pediatric formulations, with the latter under development to cover the full population spectrum.
• TPOC is currently approved for smallpox treatment in the U.S., Canada, EU, UK, and Japan, with sales to over 30 countries.
• European market strategy focuses on shifting stockpiling paradigms from vaccine-centric to a combined vaccine and antiviral approach.

Market and Competitive Landscape:

• Geopolitical tensions and AI advancements are reshaping the biological threat landscape, reinforcing the need for proactive government investment in medical countermeasures.
• International customers, particularly Canada, are demonstrating strong leadership in smallpox preparedness, validating the company's global distribution strategy.
• European preparedness spending is increasing, with competitors like Bavarian Nordex securing new UK contracts, though the sector traditionally relies heavily on vaccines.
• The company views the U.S. and international markets as increasingly aligned with a comprehensive stockpile model including both vaccines and therapeutics.

Risks and Challenges:

• Procurement timing for new U.S. government contracts remains uncertain and subject to unpredictable delays.
• Regulatory delays in the PEP program (NDA filing pushed to 2028) due to additional FDA laboratory validation requirements.
• Quarterly financial results exhibit inherent variability due to the episodic nature of government procurement cycles.
• Changing regulatory labels in Europe (e.g., NPOX label removal) may require additional discussions and impact short-term timing, though long-term opportunities remain intact.

Management Commentary and Tone:

• Management maintained a confident and mission-focused tone, emphasizing the critical national security role of TPOC and the enduring case for biodefense preparedness.
• Tone remained resilient regarding U.S. contract delays, citing bipartisan support for biodefense funding and lack of expected impact from midterm elections on budget trajectories.
• CEO Zem Nguyen and CFO Dan Luxhire highlighted a "strong balance sheet" as a key strategic advantage to sustain operations during uncertain procurement cycles.
• Acknowledgment of retiring CSCO Dennis Herbe, recognizing his pivotal role in TPOC's development and global approval over three decades.

Analyst Questions and Answers:

• CDND Contract Specifics: CFO Dan confirmed the $15 million Canada contract is the one referenced previously, with deliveries scheduled to start in 2027, structured as equal annual deliveries over the first three years.
• Additional International Deals: Confirmed advanced discussions for another international contract, with details to be provided at the appropriate time.
• U.S. Election Impact: CEO Zem stated that historical bipartisan support for biodefense suggests no material change in funding or RFP timing following midterm elections, aside from typical transition periods.
• European Market Dynamics: Addressed concerns regarding European label changes, noting they may cause timing delays but do not alter the long-term opportunity for TPOC stockpiling; reaffirmed recent renewal of filings in the EU and UK.

Other Key Points:

• The company is actively working with the Department of War, FDA, and CDC to refine the PEP program's immunogenicity sample analysis and validation protocols.
• Management reiterated that armed forces are primary first responders in public health emergencies, underscoring the strategic value of antiviral access for military stockpiles.
• The company remains committed to its core mission of government preparedness against smallpox and other high-consequence biological threats.